Literature DB >> 11185959

Vesicular stomatitis virus (VSV) therapy of tumors.

S Balachandran1, G N Barber.   

Abstract

Vesicular stomatitis virus (VSV) is an essentially nonpathogenic negative-stranded RNA virus, the replication of which is extremely sensitive to the antiviral effects of interferon (IFN). We demonstrate here that VSV selectively induces the cytolysis of numerous transformed human cell lines in vitro, with all the morphological characteristics of apoptotic cell death. Importantly, VSV can also potently inhibit the growth of p53-null C6 glioblastoma tumors in vivo without infecting and replicating in normal tissue. With our previous findings demonstrating that primary cells containing the double-stranded RNA-activated protein kinase PKR and a functional IFN system are not permissive to VSV replication, these results suggest that signaling by IFN may be defective in many malignancies. Thus VSV might be useful in novel therapeutic strategies for targeting neoplastic disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11185959     DOI: 10.1080/713803696

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  64 in total

Review 1.  Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates.

Authors:  Guido Wollmann; Koray Ozduman; Anthony N van den Pol
Journal:  Cancer J       Date:  2012 Jan-Feb       Impact factor: 3.360

2.  Vesicular stomatitis virus modified with single chain IL-23 exhibits oncolytic activity against tumor cells in vitro and in vivo.

Authors:  James M Miller; Sarah McNulty Bidula; Troels Mygind Jensen; Carol Shoshkes Reiss
Journal:  Int J Interferon Cytokine Mediat Res       Date:  2010-05-01

3.  Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus.

Authors:  M Ahmed; S Puckett; D S Lyles
Journal:  Cancer Gene Ther       Date:  2010-08-20       Impact factor: 5.987

4.  Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.

Authors:  Guido Wollmann; Eugene Drokhlyansky; John N Davis; Connie Cepko; Anthony N van den Pol
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

5.  Oncolytic Recombinant Vesicular Stomatitis Virus (VSV) Is Nonpathogenic and Nontransmissible in Pigs, a Natural Host of VSV.

Authors:  Lauro Velazquez-Salinas; Shruthi Naik; Steven J Pauszek; Kah-Whye Peng; Stephen J Russell; Luis L Rodriguez
Journal:  Hum Gene Ther Clin Dev       Date:  2017-06       Impact factor: 5.032

6.  Advances in the mechanisms of action of cancer-targeting oncolytic viruses.

Authors:  Cun-Zhi Lin; Gui-Ling Xiang; Xin-Hong Zhu; Lu-Lu Xiu; Jia-Xing Sun; Xiao-Yuan Zhang
Journal:  Oncol Lett       Date:  2018-01-19       Impact factor: 2.967

7.  Double-stranded RNA deaminase ADAR1 increases host susceptibility to virus infection.

Authors:  Yongzhan Nie; Graeme L Hammond; Jing-Hua Yang
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 8.  Advances in oncolytic virus therapy for glioma.

Authors:  Amy Haseley; Christopher Alvarez-Breckenridge; Abhik Ray Chaudhury; Balveen Kaur
Journal:  Recent Pat CNS Drug Discov       Date:  2009-01

9.  Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.

Authors:  Candice L Willmon; Vassiliki Saloura; Zvi G Fridlender; Phonphimon Wongthida; Rosa Maria Diaz; Jill Thompson; Timothy Kottke; Mark Federspiel; Glen Barber; Steven M Albelda; Richard G Vile
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

10.  Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.

Authors:  Tommy Alain; XueQing Lun; Yvan Martineau; Polen Sean; Bali Pulendran; Emmanuel Petroulakis; Franz J Zemp; Chantal G Lemay; Dominic Roy; John C Bell; George Thomas; Sara C Kozma; Peter A Forsyth; Mauro Costa-Mattioli; Nahum Sonenberg
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-04       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.